Oramed Pharmaceuticals Inc
$ 3.80
2.70%
11 Jun - close price
- Market Cap 151,426,000 USD
- Current Price $ 3.80
- High / Low $ 3.86 / 3.70
- Stock P/E 1.41
- Book Value 5.82
- EPS 2.63
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE 0.58 %
- 52 Week High 5.01
- 52 Week Low 1.84
About
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the administration of polypeptides. The company is headquartered in New York, New York.
Analyst Target Price
$6.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-19 | 2026-03-26 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-27 | 2024-11-07 | 2024-08-14 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-10 |
| Reported EPS | 0.9128 | 0.25 | 1.13 | 0.31 | -0.19 | -0.2552 | -0.48 | 0.22 | 0.04 | 0.33 | -0.08 | -0.03 |
| Estimated EPS | None | -0.08 | -0.04 | -0.04 | -0.01 | 0.02 | -0.02 | -0.02 | 0.02 | -0.12 | -0.09 | -0.09 |
| Surprise | 0 | 0.33 | 1.17 | 0.35 | -0.18 | -0.2752 | -0.46 | 0.24 | 0.02 | 0.45 | 0.01 | 0.06 |
| Surprise Percentage | None% | 412.5% | 2925% | 875% | -1800% | -1376% | -2300% | 1200% | 100% | 375% | 11.1111% | 66.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jan 2026 | |
|---|---|
| Payment Date | 2026-01-26 |
| Amount | $0.25 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORMP
2026-05-19 21:36:00
Oramed Pharmaceuticals Inc. (ORMP) reported earnings of $38.3 million in its first quarter, with a net income of 91 cents per share. The New York-based company's adjusted losses were 16 cents per share, after accounting for non-recurring gains. This financial summary was generated using data from Zacks Investment Research.
2026-05-19 21:10:33
Oramed Pharmaceuticals Inc. reported its first-quarter 2026 results, showing no product revenue but a significant improvement in net income, reaching $38.31 million compared to a net loss in the prior year. Diluted EPS was $0.91 for Q1 2026. The company's strategic shift to an active operator of a medical technology portfolio involved reduced R&D spending, key acquisitions, and advancements in clinical trials and operational milestones.
2026-05-19 21:08:33
Oramed Pharmaceuticals (NASDAQ: ORMP) reported a Q1 2026 net profit of $38.3 million, a significant turnaround from a $7.6 million loss in the prior year, primarily driven by substantial net financial income of $44.8 million from fair value gains on investments, including Alpha Tau and Scilex. Despite recording no revenue for the quarter and an operating loss of $3.7 million, the company's financial performance was bolstered by investment revaluations and an $8.3 million gain from an IP sale and license recognition. Oramed's strategic shift involves operating medical technology businesses and managing a portfolio of structured investments, with total assets increasing to $268.8 million while cash reserves decreased to $13.2 million.
2026-05-19 16:36:00
Oramed Pharmaceuticals Inc. (ORMP) reported earnings of $38.3 million in its first quarter, with a net income of 91 cents per share. The New York-based company's adjusted losses, excluding non-recurring gains, were 16 cents per share. This financial snapshot was generated using data from Zacks Investment Research.
2026-05-19 14:36:00
Oramed Pharmaceuticals Inc. (ORMP) reported first-quarter earnings of $38.3 million, translating to a net income of 91 cents per share. After adjusting for non-recurring gains, the New York-based company incurred a loss of 16 cents per share. This financial snapshot was generated using data from Zacks Investment Research.
2026-05-18 22:10:40
Lifeward Ltd. reported a net loss of $10.8 million for the three months ended March 31, 2026, driven by a significant increase in research and development expenses due to the Oratech acquisition. The company's total revenues decreased to $3.9 million, primarily from lower AlterG sales, while operating cash burn reduced by 33% year-over-year. Lifeward continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and negative operating cash flows, despite recent financing activities.
